Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.12 USD
Change Today 0.00 / 0.00%
Volume 211.4K
ACRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

acelrx pharmaceuticals inc (ACRX) Snapshot

Open
$4.14
Previous Close
$4.12
Day High
$4.20
Day Low
$4.04
52 Week High
02/26/15 - $9.32
52 Week Low
05/5/15 - $2.96
Market Cap
182.7M
Average Volume 10 Days
558.9K
EPS TTM
$-0.95
Shares Outstanding
44.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACELRX PHARMACEUTICALS INC (ACRX)

acelrx pharmaceuticals inc (ACRX) Related Bloomberg News

View More Bloomberg News

acelrx pharmaceuticals inc (ACRX) Related Businessweek News

No Related Businessweek News Found

acelrx pharmaceuticals inc (ACRX) Details

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company’s lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

36 Employees
Last Reported Date: 05/5/15
Founded in 2005

acelrx pharmaceuticals inc (ACRX) Top Compensated Officers

Co-Founder, Chief Medical Officer and Directo...
Total Annual Compensation: $421.0K
Chief Financial Officer and Head of Business ...
Total Annual Compensation: $288.4K
Chief Development Officer
Total Annual Compensation: $310.3K
Chief Engineering Officer
Total Annual Compensation: $310.3K
Compensation as of Fiscal Year 2014.

acelrx pharmaceuticals inc (ACRX) Key Developments

AcelRx Pharmaceuticals Entered into the First Amendment to the Collaboration and License Agreement with Gr nenthal GmbH

On July 22, 2015, AcelRx Pharmaceuticals entered into the first amendment effective as of July 17, 2015, to the collaboration and license agreement between AcelRx and Gr nenthal GmbH, effective as of December 16, 2013 and the first amendment effective as of July 17, 2015, to the related Manufacture and Supply Agreement, between AcelRx and Gr nenthal, effective as of December 16, 2013. The License Agreement grants Gr nenthal rights to commercialize Zalviso (formerly known as ARX-01), AcelRx's novel sublingual patient-controlled analgesia (PCA) system in the countries of the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings. AcelRx retains rights with respect to the Product outside of the Field as well as in countries outside the Territory, including the U.S., Asia and Latin America. The MSA provides for AcelRx to manufacture and supply the Product for use in the Field for the Territory exclusively for Gr nenthal. In the MSA Amendment and License Amendment, the parties amended the Product supply configurations and packaging of Product components and accessories, and associated pricing therefor, which AcelRx will manufacture and supply to Gr nenthal for the Territory. As consideration for an increase in the pricing of the Product components and accessories as part of the agreed packaging configurations, the total milestone payments from Gr nenthal contingent upon achieving specified net sales target milestones were reduced from a total of $171.5 million to $166.0 million. The parties also amended the development plan for the Product in the Territory, providing for additional near-term development costs to be paid by Gr nenthal.

AcelRx Pharmaceuticals, Inc. Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients

AcelRx Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual tablet system). The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational drug-device combination product designed to deliver a sublingual formulation of sufentanil 15 mcg through a proprietary pre-programmed, non-invasive, patient-controlled device. Grunenthal Group, AcelRx’s licensee in Europe, submitted the Marketing Authorization Application (MAA) under the centralized procedure in July of 2014. The positive opinion by the CHMP will next be reviewed by the European Commission for central marketing authorization in the European Union (EU), which has the authority to approve medicines for the 28 member countries of the EU which will also be valid in Norway, Iceland and Liechtenstein. If approved, Grunenthal expects to launch Zalviso beginning in the first half of 2016. In addition, AcelRx would be eligible to receive a $15 million milestone payment from Grunenthal upon approval.

AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 2000 Index

AcelRx Pharmaceuticals, Inc. will be removed from Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACRX:US $4.12 USD 0.00

ACRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACRX.
View Industry Companies
 

Industry Analysis

ACRX

Industry Average

Valuation ACRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.1x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACELRX PHARMACEUTICALS INC, please visit www.acelrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.